FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
FDA General

Stop Inaccurate Health Info: HHS Staff to RFK, Jr.

Some 750 current and former HHSers call on secretary Robert F. Kennedy, Jr., to protect them and the rest of his staff from attacks by ending his inac...

Medical Devices

FDA Updates Breakthrough Device Statistics

Updated medical device breakthrough device designation metrics show 1,176 approvals since 2015 and 160 marketing authorizations.

latest-news-card-1
Medical Devices

FDA DrugSorb-ATR Options

FDA suggests ways CytoSorbents can proceed with its de novo application for DrugSorb-ATR.

latest-news-card-1
Human Drugs

Act Against Compounded Semaglutide: Petition

Wiley Rein petitions FDA to take seven specific actions to address public health risks associated with compounded semaglutide drug products.

latest-news-card-1
Biologics

2 Eylea HD Submissions Get Review Extensions

FDA extends until the fourth quarter the review of two Regeneron Pharmaceuticals regulatory submissions for Eylea HD (aflibercept) injection 8 mg regu...

latest-news-card-1
Human Drugs

B. Braun Recalls 2 Drugs Over Particulate Matter

B. Braun Medical recalls (Class 1) one lot each of its Lactated Ringers Injection USP 1,000 mL and 0.9% sodium chloride injection USP 1,000 mL due to...

latest-news-card-1
Human Drugs

CGMP Violations Seen in Anhui Hanbon Inspection

FDA warns Chinas Anhui Hanbon Daily Chemical Co. about CGMP violations in its production of finished drugs.

latest-news-card-1
FDA General

FDA Pushes Back Review of Hunter Syndrome BLA

FDA extends by 90 days its review of a Regenxbios BLA for RGX-121 (clemidsogene lanparvovec), an investigational gene therapy for Hunter syndrome.

latest-news-card-1
Human Drugs

PTC Therapeutics Friedreichs Ataxia Drug Rejected

FDA rejects a PTC Therapeutics NDA for vatiquinone and its use for treating Friedreichs ataxia, saying additional evidence of the drugs effectiveness ...

latest-news-card-1
Human Drugs

Clinical Hold on BiomX Cystic Fibrosis Therapy

FDA places a clinical hold on a BiomX Phase 2b trial of BX004, an investigational phage therapy for cystic fibrosis.